Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

NASDAQ:TRVI

Trevi Therapeutics, Inc.

Last Close

3.01

03/05 17:42

Market Cap

99.62M

Beta: 0.69

Volume Today

11.54K

Avg: 82.90K

PE Ratio

−5.22

PFCF: −2.81